Ocular Therapeutix Inc (OCUL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.37B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ocular Therapeutix Inc (OCUL) Stock Forecast
Analysts expect Ocular Therapeutix (OCUL) to earn -$1.51 per share in the fiscal year ending Dec 31, 2026, on revenue of $51.00M. Of 12 analysts, 12 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 33.3% |
| Buy | 8 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 78.8%.
- Fiscal year ending Dec 31, 2026
- -$1.51
- EPS consensus, revenue $51.00M
- Fiscal year ending Dec 31, 2027
- -$1.60
- EPS consensus, revenue $91.18M
- Next report
- Feb 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.51 | -$1.65 to -$1.27 | 5 | $51.00M | $50.00M to $53.49M | 11 |
| Dec 31, 2027 | -$1.60 | -$1.86 to -$1.09 | 6 | $91.18M | $50.50M to $183.00M | 12 |
Quarterly Estimates
The EPS consensus rises from -$0.42 for the quarter ending Dec 31, 2026 to -$0.38 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.42 | -$0.44 to -$0.39 | 15 | $14.03M | $12.61M to $17.17M | 15 |
| Mar 31, 2027 | -$0.38 | -$0.43 to -$0.34 | 6 | $12.27M | $11.00M to $13.30M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 9 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Fiscal year ending Dec 31, 2027 | 3 | 1 |
| Quarter ending Mar 31, 2027 | 3 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.43.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.51 | -$1.44 | -$1.43 | -$1.43 | -$1.43 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.60 | -$1.48 | -$1.45 | -$1.45 | -$1.45 | N/A |
| Quarter ending Mar 31, 2027 | -$0.38 | -$0.37 | -$0.37 | -$0.37 | -$0.37 | N/A |
Frequently Asked Questions About OCUL
What is the OCUL stock forecast?
Consensus analyst estimates put Ocular Therapeutix's EPS at -$1.51 for the fiscal year ending Dec 31, 2026, on revenue of $51.00M. The consensus rating from 12 analysts is Buy.
How do analysts rate OCUL stock?
Of 12 analysts covering Ocular Therapeutix, 4 rate it Strong Buy, 8 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from OCUL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.51, with estimates from -$1.65 to -$1.27 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.60, with estimates from -$1.86 to -$1.09 from 6 analysts.
What revenue do analysts expect from Ocular Therapeutix next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $51.00M, with estimates from $50.00M to $53.49M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $91.18M, with estimates from $50.50M to $183.00M.
How many analysts cover OCUL?
12 analysts rate Ocular Therapeutix stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
OCUL pages: Overview, Earnings, Forecast, Financials, Competitors